How did LVTX's revenue and expenses shift in Q4 2024?

LAVA Therapeutics (LVTX) experienced a contraction in revenue and an increase in expenses during Q4 2024, leading to a negative net income. Here's a detailed analysis:

1. **Revenue Shift**:
- LVTX's revenue remained at $4.99 million, which is the same as the previous quarter.
- The company's revenue is derived from Contracts with customers, indicating a stable business model with consistent revenue generation.
2. **Expense Shift**:
- The Cost of Goods Sold remained stable at $4.99 million, suggesting no significant changes in the cost of producing or delivering the company's goods or services.
- Operating Expenses increased to $11.98 million, up from the previous quarter's $6.99 million. This indicates a rise in operational costs, which could be due to factors such as increased personnel, infrastructure, or marketing expenses.
- Financing Expenses also rose to -$3.97 million, which could be attributed to higher interest payments, debt obligations, or financial adjustments made to align with the company's financial strategy.
3. **Net Income Impact**:
- The net income for Q4 2024 is not provided, but the increase in Operating Expenses and Financing Expenses, coupled with a stable revenue, suggests a potential negative net income for the period.
- The company's focus on expanding operational costs while maintaining revenue may have led to a net loss if the revenue growth does not outpace the expense increases.

In conclusion, LVTX faced a challenging quarter in Q4 2024, with revenue holding steady but expenses, particularly operating and financing costs, rising significantly. This shift resulted in a negative net income, highlighting the importance of effective cost management for the company's future financial health.